If you have suffered from an Exactech knee implant failure, you could be eligible for compensation.

The FDA’s adverse events database has received notices that patients are experiencing Exactech Optetrak artificial knee failures as a result of the tibial insert wearing out quickly.

Orthopaedics & Traumatology: Surgery & Research published a study of 110 Optetrak cemented knee implants implanted between 2005 and 2007. An independent observer followed up with patients between 12 and 42 months, with the mean follow-up time of 25 months.

Seventeen patients with an Exactech knee implant reportedly were “disappointed or dissatisfied” and 25 knees were so painful that the patients needed painkilling medications.

The joint where the femur and kneecap meet is called the patellofemoral joint. While 25 prostheses in the study indicated tibial implant loosening, another 24 showed signs of patellofemoral problems.

In less than five years, 13 Exactech knee implants were revised due to tibial loosening, patellofemoral instability or patellofemoral pain.

Patients experiencing pain, mobility issues, swelling, fluid retention in the joint, instability, or a warm and inflamed joint might be in need of an Exactech knee implant revision surgery.

Exactech Knee Implant Recalls

In the fall of 2017, the FDA announced a Class 2 device recall of the Optetrak Offset Tibial Tray and Screws. According to Exactech’s reason for the recall, a design incompatibility exists between certain sizes of screws and the tibial insert when they are used in conjunction with an offset tibial tray.

Previously, in 2012, the Optetrak Logic Posterior Stabilized Tibial Insert, Size 6 was recalled due to a defective design.

Exactech has produced a variety of Optetrak knee devices since 1994.

The FDA’s Manufacturer and User Facility Device Experience (MAUDE) reports allege revision surgeries were needed due to “loose tibial component” and “pain, limited mobility, knee swelling and sensitivity.”  Similar complaints reportedly were received in 2013.

Exactech Merges with TPG Capital

Exactech merged with TPG Capital in February. Up until Feb. 15, 2018, Exactech was traded on the Nasdaq as EXAC. The $737 million deal means Exactech is now part of TPG’s $73 billion of assets.

In 2016, Exactech CEO and President David Petty said,“We are pleased with our strong performance in 2016 and we believe we are well positioned for another solid year in 2017. The 2016 results reflect excellent surgeon acceptance of Exactech innovations, including our three new revision systems, as well as the positive impact of our sales channel development strategy.”

Patients who have undergone an Exactech knee implant surgery prefer to avoid revision surgery. Revision surgery puts them at greater risk of complications. A patient who receives a knee revision surgery faces an increased risk of blood clots, bone loss and infection.

Damage to nerves, tissue and blood vessels is more apt to occur during a revision surgery. Sometimes, one leg ends up shorter than the other due to bone loss from successive surgeries.

If you have undergone an Exactech knee implant surgery and suffered adverse side effects or needed revision surgery, you could qualify for compensation through legal representation.

Get a Free Knee Replacement Case Review

If you or a loved one suffered from complications caused by an Attune knee implant, an Arthrex knee implant, or an Exactech knee implant, you may have a legal claim. In general, knee replacement surgery lawsuits are filed individually by each plaintiff and are not class actions. Get help now by filling out the form on this page for a FREE case evaluation.

Learn More